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A Ab bs st tr ra ac ct t
Cancer is the most common acquired genetic disease. Great progress has been made in
documenting the genetic abnormalities that cause the disease, and in the future each tumor will
be subjected to genetic analysis and the appropriate combination of drugs selected. Although
there are serious technological and cost hurdles to surmount and resistance and continued
mutation will be a constant problem, the way is clear to rational therapy.
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The explosion in the knowledge of cancer genetics of the past
25 years has totally changed our approach to cancer
treatment. Indeed, we are in the midst of a cancer treatment
revolution [1]. But, as is true of many political and cultural
revolutions, the pace of progress is maddeningly ponderous.
Although recent relaxations of the grips of smoking and
hormone replacement therapy has led to a welcome decline
in cancer incidence [2], millions more lives will be lost
before we truly understand or have the tools to provide
effective therapy for this vastly complex group of diseases.
Despite the long road ahead, investigators, clinicians and
patients share a mounting confidence that new therapeutic
research will ultimately be successful. Through oncoge-
netics, we will be able to document the drivers of an
individual cancer and delineate the gain-of-function
mutations that give rise to growth-promoting proteins that
in turn induce oncogene ‘addiction’, in which a cancer is
dependent on such proteins. We will also determine the loss-
of-function mutations that deprive cancer cells of the
proteins that direct DNA repair and/or provide directions to
the cell death pathway. Armed with such oncogenetic data,
we will match the validated mutations of a particular cancer
to an appropriate and scientifically determined targeted
drug array. This great challenge, one akin to President
Kennedy’s thrust to the moon, is definitely possible. Here,
we provide the background to our optimism and also
describe some of the roadblocks that obstruct the path of
progress.
Modern treatment of invasive cancers that have extended
beyond the reach of the surgeon’s knife or the radiation
therapist’s beam began in the post World War II era when
Sidney Farber and his colleagues introduced aminopterin to
induce remissions in childhood leukemia [3]. Farber was
committed to sequential application of single agents and
urged an extensive public and private antibiotic and anti-
cancer drug screening program to produce many active
compounds that had in common the induction of injuries to
cell DNA or the process of cell division. These were
eventually used in various combinations with the intent of
achieving selective toxicity and minimizing resistance. The
results were variable. After 50 years of almost entirely
empirical clinical trials, combination chemotherapy moved
the prognosis of standard childhood leukemia from
invariably fatal to an 85% cure rate [4]. The outcome of
systemic Hodgkin’s Disease was similarly improved. Clear-
cut benefit was established in breast, head and neck,
ovarian, testicular and colon cancer. But very little progress
was made in lung, prostate, liver, pancreas or brain cancer,and the toxicities of the treatments remain considerable -
normal cells as well as cancer cells are badly injured in the
process. Although surgery, radiation therapy and combina-
tion chemotherapy have made an impact on the disease,
early and late side effects are significant. Towards the end of
the 20th century it became clear that the efficacy of this
‘carpet-bombing’ treatment of cancer had reached a plateau.
During this period of trial and error some critically impor-
tant concepts of cancer pathophysiology have been realized.
Chromosomes in the leukemias and lymphomas may appear
normal but frequently show translocations and deletions
that provide clues to the relatively few genes that are
responsible for such tumors [4]. In contrast, the chromo-
somes in epithelial cancer cells are almost always broadly
and heavily damaged [5]. The chromosome wreckage
includes massive deletions, amplifications and rearrange-
ments, as well as point mutations and translocations, and
can be observed in very early stages of the growth of such
tumors. The latter observation suggests that several mutated
genes in an individual cancer may be responsible for the
malignant state and that many more are mere accidents of
the chromosome breakage. The art of oncogenetics lies in
validating the relatively few significant mutations and
differentiating them from the many innocuous byproducts of
the chromosome breakdown that characterizes the epithelial
cancer process. Put simply, the epithelial cancer problem
can be understood and effectively treated only by documen-
tation of the truly oncogenic results of widespread DNA
damage. This demonstrates the critical importance of
advances in the detection of cancer-causing genes.
The role of cancer genetics as a discipline that would
probably lead to more effective targeted treatment was
highlighted by the discovery of a gain-of-function Abl kinase
gene that produced hyperactive Abl kinase, a unique driver
of early stage chronic myelogenous leukemia [6,7]. In fact
the successful interruption of unbridled Abl kinase activity
by imatinib ushered in a new era of ‘smart drug’ treatment of
cancer [8]. In this new era, three major paths of progress
have been and continue to be explored. The first has used
patient-derived cancers, transgenic mice [9] and transfected
cells [10], DNA and RNA (including microRNA) array tech-
nology [11] and gene sequencing [12] to establish potential
genetic drivers of the initiation and maintenance of cancer
cell growth. The second approach has focused on the failure
of human and murine cancer cells either to repair their
damaged DNA [13] or, without DNA repair, to plunge fatally
into a metabolic death pathway [14]. Both failures contribute
to the malignant process, particularly in the common human
epithelial cancers and also in certain lymphomas.
A third and more recent approach has examined the organ
environment of cancer and has revealed that the stromal
fibroblasts surrounding cancer cells, such as ductal carci-
nomas, exude signals that break down the myoepithelial cell
barrier that would otherwise confine the cancer cells to the
duct [15-17]. Furthermore, certain cancers, such as neuro-
fibromas that arise as a result of homozygous loss-of-
function mutations of a tumor suppressor gene (NF1), do not
become actual tumors unless their surrounding stromal cells
lack one of the two copies of the gene [18]. Finally, some
cancers induce supporting cells to maintain cancer cell
viability. This effect includes but is not limited to vascular
endothelial cells [19].
In all three of these areas of oncogenetic research, drugs and
antibodies have been sought that would either block gain-of-
function proteins or replace key loss-of-function proteins. A
considerable effort has also been expended to produce
murine models of epithelial cancers so as to hasten the
development of effective therapies [20]. While this extensive
basic research has been in progress, clinical scientists have
been exploring the many ‘smart drugs’ that have come off
the assembly lines of pharmaceutical companies. What have
been the results of all of this effort?
Among the first waves of research have been discoveries of
the genetic drivers of common and uncommon cancers.
Breast cancers, whether acquired or (rarely) inherited, are
prime examples. Despite vast chromosome damage and
multiple mutations, most breast cancers are largely
maintained by overexpression or possibly (and contested)
amplification of the estrogen and progesterone receptor
genes [21]. Simple estrogen receptor blockade or inhibition
of estrogen synthesis combined with limited surgery and
radiation therapy and ordinary combination chemotherapy
can cure up to 80% of these cancers if they are diagnosed
before widespread disease has occurred [22]. In approxi-
mately 20% of cases a different mutation is responsible for
the malignant state. In those less common cases the cause is
amplification of Her2-neu, a receptor kinase gene that
expresses a subtype of an epidermal growth factor receptor
[23]. Such Her2-neu-positive cases have, until recently, been
burdened by a very poor prognosis. However, recent clinical
studies have demonstrated that early infusions of
traztuzumab, a monoclonal antibody directed against the
receptor, combined with standard treatment markedly
improves the outlook for these heretofore unfortunate
patients [24]. The third major subtype of breast cancer,
representing about 15% of cases, includes the so-called
basal-like or triple-negative tumors that lack estrogen and
progesterone receptors and Her2-neu and have not been
amenable to targeted therapy. Recently, however, advantage
has been taken of the resemblance of these tumors to those
of the rare BRCA1 mutation carriers who have a high rate of
inherited breast cancer. BRCA1 and BRCA2 are DNA repair
genes; they thus provide protection from DNA cross-linking
agents, such as radiation or cisplatinum. Basal-like tumors
are therefore sensitive to cisplatinum and poly ADP ribose
polymerase (PARP) inhibitors, an excellent example of how
inquiries into cancer genetics improve cancer therapy.
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fatal sarcoma that, in its advanced stages, also shows severe
chromosomal damage, can be obliterated by imatinib [25].
Resistance generally (but not always) occurs when the drug
is used as a single agent, but the dramatic effect of imatinib
proves that such tumors become dependent on or addicted
to mutated tyrosine kinases (in this case Kit or platelet
derived growth factor receptor). The dramatic therapeutic
results provide a remarkable example of the value of a single
drug that can interrupt more than one of the gain-of-
function proteins that drive such tumors [26]. Given that
there are over 500 protein kinases in the human ‘kinome’,
major efforts are now in place to define their roles in the
hundreds of fatal cancers. Slowly but surely, incriminating
evidence is being gathered that implicates previously
unsuspected kinase mutations in various cancers. Neuro-
blastoma is an excellent recent example [27].
In addition to kinase drivers, the genes of other growth
promoters, including transcription factors such as Myc or
signaling proteins such as Wnt, have been shown to be
mutated or amplified in many different cancers [28]. They
surely have an important role in the maintenance of
unbridled growth. Indeed, mutations of kinases seem to be
relatively uncommon causes of cancer, although they are the
subjects of recent excitement.
Finally, loss-of-function mutations of DNA repair genes
prevent the repair of cancer-inducing genes [29], and the
frequently observed loss or inactivation of genes such as p53
and MDM2 reduces the capacity of injured cancer cells to
quit the cellular scene by means of apoptosis [30]. This leads
to cancer-cell immortality and failure of cancer chemo-
therapy and radiotherapy to achieve cancer cell death. In an
entirely novel approach to drug development, peptides
‘stapled’ by fatty acids have been used as effective experi-
mental drugs that replace such missing proteins [31].
As DNA sequencing and array technology advances, investi-
gators are churning out vast amounts of genetic information
about common cancers, such as colon, breast, prostate,
pancreas, lung and glioblastoma [32-36], and about unusual
cancers, such as mesothelioma [37]. Recently, the entire
DNA sequence of a single case of acute myelogenous
leukemia that had a normal karyotype was published. In
addition to two previously described genetic abnormalities,
six previously unappreciated mutations were observed [38].
However, much of the data derived from such massive
efforts may be misleading. It is likely that only a few of the
detected DNA variations that emerge from complete DNA
sequencing will actually prove to be responsible for the
tumors. The immense task is to sort through them and
define them and then develop the drugs to either block or
replace them. Then we must face the pernicious problems of
genetic or epigenetic mutational heterogeneity among the
cells in a single tumor and of continued mutation. If we have
the appropriate drugs, can we kill the cancer cells before
they mutate again to develop new drivers that were not
present before our new therapy was launched? We need to
develop the tools that will allow us to define tumor genetic
and epigenetic heterogeneity.
Even when we solve those diagnostic problems (and we will),
we and our patients face yet another barrier. It is already
very clear that the new ‘smart drug’ era does not imply that
we will be successful very often with single agents. Cancer
cells with extra-labile DNA will mutate to circumvent smart
drugs very easily. This means that we must treat patients
with combinations of drugs that block multiple metabolic
pathways. Toxicity may become a very severe problem as we
force patients down that route.
Despite all these caveats, excitement is in the air. We are on
the verge of understanding the biology of cancer, and with
that understanding will come the drugs that will help us to
beat it down. We may not actually cure all or even many of
our previously unmanageable patients, but we will convert
such cancers from killers to chronic smoldering illnesses
that can be endured. Our goal will be to provide cancer
sufferers with a fulfilling life. This objective has been
achieved in many cases of AIDS. We will surely get at least
that far for patients with cancer. It will take years of hard
work, but we owe that commitment to the cancer patients
who rely on us for a better future. A thorough understanding
of oncogenetics will show us the way.
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